Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Aug;41(8):1731–1734. doi: 10.1128/aac.41.8.1731

Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.

M Paul 1, R Durand 1, H Fessi 1, D Rivollet 1, R Houin 1, A Astier 1, M Deniau 1
PMCID: PMC163994  PMID: 9257750

Abstract

The efficacy of a new liposomal formulation of amphotericin B was compared to that of amphotericin B deoxycholate (Fungizone) in a murine model of visceral leishmaniasis induced by Leishmania infantum. Median effective doses (ED50) were determined with two different strains: strain 1 was obtained from an untreated patient, and strain 2 was obtained from a patient who had received 12.5 g of amphotericin B over 3 years. BALB/c mice were infected intravenously on day 0 with promastigotes and then treated on days 14, 16, and 18 (strain 1) or on days 21, 23, and 25 (strain 2) with the liposomal formulation of amphotericin B (five doses were tested for each strain: 0.05, 0.1, 0.5, 0.8, and 3 mg/kg of body weight) or with conventional amphotericin B (four doses were tested for each strain: 0.05, 0.1, 0.5, and 0.8 mg/kg). Mice in the control group received normal saline solution. The liposomal amphotericin B formulation was about three times more active than the conventional drug against both strains. ED50 of the liposomal formulation were 0.054 (strain 1) and 0.194 (strain 2) mg/kg. ED50 of conventional amphotericin B were 0.171 (strain 1) and 0.406 (strain 2) mg/kg. Determination of drug tissular levels, 3 days after the last drug administration, showed a drug accumulation in hepatic and splenic tissues much higher after administration of liposomal amphotericin B than after conventional amphotericin B. A lack of toxicity was noted in all groups treated with the liposomal formulation.

Full Text

The Full Text of this article is available as a PDF (164.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altés J., Salas A., Riera M., Udina M., Galmés A., Balanzat J., Ballesteros A., Buades J., Salvá F., Villalonga C. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS. 1991 Feb;5(2):201–207. [PubMed] [Google Scholar]
  2. Alvar J., Gutiérrez-Solar B., Molina R., López-Velez R., Garcia-Camacho A., Martinez P., Laguna F., Cercenado E., Galmes A. Prevalence of Leishmania infection among AIDS patients. Lancet. 1992 Jun 6;339(8806):1427–1427. doi: 10.1016/0140-6736(92)91255-7. [DOI] [PubMed] [Google Scholar]
  3. Berman J. D., Hanson W. L., Chapman W. L., Alving C. R., Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother. 1986 Dec;30(6):847–851. doi: 10.1128/aac.30.6.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carter K. C., Dolan T. F., Alexander J., Baillie A. J., McColgan C. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol. 1989 Feb;41(2):87–91. doi: 10.1111/j.2042-7158.1989.tb06399.x. [DOI] [PubMed] [Google Scholar]
  5. Croft S. L., Davidson R. N., Thornton E. A. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):111–118. doi: 10.1093/jac/28.suppl_b.111. [DOI] [PubMed] [Google Scholar]
  6. Davidson R. N., Croft S. L., Scott A., Maini M., Moody A. H., Bryceson A. D. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet. 1991 May 4;337(8749):1061–1062. doi: 10.1016/0140-6736(91)91708-3. [DOI] [PubMed] [Google Scholar]
  7. Davidson R. N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G. B., Pempinello R., Scott S., Raimondi F., Cascio A. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med. 1994 Feb;87(2):75–81. [PubMed] [Google Scholar]
  8. Davidson R. N., di Martino L., Gradoni L., Giacchino R., Gaeta G. B., Pempinello R., Scotti S., Cascio A., Castagnola E., Maisto A. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996 Jun;22(6):938–943. doi: 10.1093/clinids/22.6.938. [DOI] [PubMed] [Google Scholar]
  9. Dereure J., Reynes J., Pratlong F., Lamaury I., Rioux J. A., Janbon F., Dedet J. P. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull World Health Organ. 1995;73(2):245–246. [PMC free article] [PubMed] [Google Scholar]
  10. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996 Sep-Oct;14(5):417–423. doi: 10.1016/0738-081x(96)00057-0. [DOI] [PubMed] [Google Scholar]
  11. Fillola G., Corberand J. X., Laharrague P. F., Levenes H., Massip P., Recco P. Peripheral intramonocytic leishmanias in an AIDS patient. J Clin Microbiol. 1992 Dec;30(12):3284–3285. doi: 10.1128/jcm.30.12.3284-3285.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fusai T., Deniau M., Durand R., Bories C., Paul M., Rivollet D., Astier A., Houin R. Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model. Parasite. 1994 Dec;1(4):319–324. doi: 10.1051/parasite/1994014319. [DOI] [PubMed] [Google Scholar]
  13. Gangneux J. P., Sulahian A., Garin Y. J., Farinotti R., Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother. 1996 May;40(5):1214–1218. doi: 10.1128/aac.40.5.1214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548. doi: 10.1128/aac.33.9.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gradoni L., Bryceson A., Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ. 1995;73(2):191–197. [PMC free article] [PubMed] [Google Scholar]
  16. Gradoni L., Davidson R. N., Orsini S., Betto P., Giambenedetti M. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target. 1993;1(4):311–316. doi: 10.3109/10611869308996089. [DOI] [PubMed] [Google Scholar]
  17. Hiemenz J. W., Walsh T. J. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996 May;22 (Suppl 2):S133–S144. doi: 10.1093/clinids/22.supplement_2.s133. [DOI] [PubMed] [Google Scholar]
  18. Legrand P., Vertut-Doi A., Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother. 1996 Mar;37(3):519–533. doi: 10.1093/jac/37.3.519. [DOI] [PubMed] [Google Scholar]
  19. Matheron S., Cabié A., Parquin F., Mayaud C., Roux P., Antoine M., Chougnet C., Coulaud J. P. Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis. AIDS. 1992 Feb;6(2):238–240. [PubMed] [Google Scholar]
  20. Mishra M., Biswas U. K., Jha A. M., Khan A. B. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet. 1994 Dec 10;344(8937):1599–1600. doi: 10.1016/s0140-6736(94)90406-5. [DOI] [PubMed] [Google Scholar]
  21. Montalban C., Calleja J. L., Erice A., Laguna F., Clotet B., Podzamczer D., Cobo J., Mallolas J., Yebra M., Gallego A. Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect. 1990 Nov;21(3):261–270. doi: 10.1016/0163-4453(90)93933-j. [DOI] [PubMed] [Google Scholar]
  22. New R. R., Chance M. L., Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother. 1981 Nov;8(5):371–381. doi: 10.1093/jac/8.5.371. [DOI] [PubMed] [Google Scholar]
  23. Oliva G., Gradoni L., Ciaramella P., De Luna R., Cortese L., Orsini S., Davidson R. N., Persechino A. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother. 1995 Dec;36(6):1013–1019. doi: 10.1093/jac/36.6.1013. [DOI] [PubMed] [Google Scholar]
  24. Olsen S. J., Swerdel M. R., Blue B., Clark J. M., Bonner D. P. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol. 1991 Dec;43(12):831–835. doi: 10.1111/j.2042-7158.1991.tb03189.x. [DOI] [PubMed] [Google Scholar]
  25. Peters B. S., Fish D., Golden R., Evans D. A., Bryceson A. D., Pinching A. J. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med. 1990 Nov;77(283):1101–1111. doi: 10.1093/qjmed/77.2.1101. [DOI] [PubMed] [Google Scholar]
  26. Proffitt R. T., Satorius A., Chiang S. M., Sullivan L., Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):49–61. doi: 10.1093/jac/28.suppl_b.49. [DOI] [PubMed] [Google Scholar]
  27. Rosenthal E., Marty P., Poizot-Martin I., Reynes J., Pratlong F., Lafeuillade A., Jaubert D., Boulat O., Dereure J., Gambarelli F. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg. 1995 Mar-Apr;89(2):159–162. doi: 10.1016/0035-9203(95)90476-x. [DOI] [PubMed] [Google Scholar]
  28. Scaglia M., Villa M., Gatti S., Gianelli F., Fabio F. Cutaneous leishmaniasis in acquired immunodeficiency syndrome. Trans R Soc Trop Med Hyg. 1989 May-Jun;83(3):338–339. doi: 10.1016/0035-9203(89)90494-x. [DOI] [PubMed] [Google Scholar]
  29. Torre-Cisneros J., Villanueva J. L., Kindelan J. M., Jurado R., Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis. 1993 Oct;17(4):625–627. doi: 10.1093/clinids/17.4.625. [DOI] [PubMed] [Google Scholar]
  30. Wang L. H., Smith P. C., Anderson K. L., Fielding R. M. High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies. J Chromatogr. 1992 Sep 2;579(2):259–268. doi: 10.1016/0378-4347(92)80390-c. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES